Mozobil vs Plerixafor: Side-by-Side Comparison
Quick answer: Mozobil and Plerixafor are both hematopoietic stem cell mobilizer (cxcr4 antagonist) used for similar indications. They share a mechanism of action but differ in dosing, half-life, side-effect profile, and clinical preferences. Switching between them is a clinical decision.
Side-by-side comparison
| Feature | Mozobil | Plerixafor |
|---|---|---|
| Drug class | Hematopoietic stem cell mobilizer (CXCR4 antagonist) | Hematopoietic stem cell mobilizer (CXCR4 antagonist) |
| ATC code | L03AX16 | L03AX16 |
| Primary indications | Stem cell mobilization in non-Hodgkin lymphoma, Multiple myeloma (autologous transplant) | Stem cell mobilization in non-Hodgkin lymphoma, Stem cell mobilization in multiple myeloma |
| Mechanism | Plerixafor reversibly inhibits CXCR4 chemokine receptor binding to SDF-1α, mobilizing hematopoietic stem cells from bone marrow to peripheral blood | CXCR4 chemokine receptor antagonist that mobilizes hematopoietic stem cells from bone marrow into peripheral blood |
| Common dose | 0.24 mg/kg subcutaneously once daily | 0.24 mg/kg subcutaneously once daily |
| Detail page | Mozobil details → | Plerixafor details → |
How to choose between Mozobil and Plerixafor
Both medicines belong to the same therapeutic class and address overlapping indications. Selection between them depends on:
- Patient-specific factors: age, kidney and liver function, other medications, allergies, comorbidities
- Specific clinical indication: some class members are preferred for particular conditions or guideline recommendations
- Dosing preference: once-daily vs twice-daily, oral vs injectable, food requirements
- Tolerability: individual side-effect profiles vary even within a class
- Drug interactions: patient's other medications may interact differently with each option
- Cost and availability: generic availability, insurance coverage, regional access
Should you switch?
Switching between class members is a clinical decision, not a self-help one. Reasons your prescriber may consider switching include:
- Inadequate response to current medication
- Side effects affecting quality of life
- New drug interactions due to a recently added medication
- Cost or availability changes
- Updated guidelines favoring a different option
Never switch medications, change dose, or stop without consulting your prescriber.
Related
All Hematopoietic stem cell mobilizer (CXCR4 antagonist) on iMedic · Mozobil full details · Plerixafor full details
Frequently asked questions
Is Mozobil better than Plerixafor?
Neither is universally 'better.' They are both hematopoietic stem cell mobilizer (cxcr4 antagonist) with similar mechanisms of action. The right choice depends on the specific clinical situation, patient factors, dosing preferences, drug interactions, and tolerability. Discuss with your prescriber.
Can I switch from Mozobil to Plerixafor?
Switching is possible but should be done under clinical supervision. Different class members may not be interchangeable on a 1:1 dose basis, and tapering or transition strategies vary. Never switch on your own.
Do Mozobil and Plerixafor have the same side effects?
They share class-wide side-effect tendencies but differ in individual profiles. Some patients tolerate one better than the other. Specific frequency and severity of side effects can be found on each medicine's individual page.
Are Mozobil and Plerixafor available as generics?
Generic availability depends on patent status in your country. Most well-established class members are available generically and are clinically equivalent to brand-name versions.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.